UTv Videos

For patients undergoing salvage surgery or radiation, Kelly L. Stratton, MD, FACS, notes that previous focal therapy can influence outcomes.

TULSA patients were treated and discharged the same day.

Laura Bukavina, MD, MPH, offered her thoughts on the significance of the KEYNOTE-905 data and highlighted some remaining questions surrounding the regimen.

Stratton emphasized that the trial’s results provide greater confidence in recommending therapy and allow clinicians to counsel patients more decisively about next steps when PSA begins to rise.

Michael S. Cookson, MD, MMHC, FACS, shares his thoughts on the most exciting recent advances in bladder cancer treatment.

Joshua J. Meeks, MD, PhD, discussed the emerging role of ctDNA in guiding adjuvant and neoadjuvant strategies in patients with bladder cancer.

In this opening segment, the discussion focuses on the rapid evolution of kidney stone surgery and how suction has transitioned from an aspirational idea to a core component of modern ureteroscopy.

Experts compare and contrast direct in-scope suction with the flexible and navigable ureteric access sheath.

Learn how suction has become central to contemporary ureteroscopic practice and how its integration is reshaping surgical decision-making, treatment algorithms, and the perceived role of percutaneous procedures.

Laser technology is expected to play a major role in the next wave of innovation.

Cameron J. Britton, MD, highlights key findings from a study of the MyProstateScore 2.0 in predicting upgrading to GG≥3 prostate cancer.

Roger Li, MD, discusses the development and validation of a CHAI-based biomarker to identify patients with LG NMIBC who are at higher risk of progression.

INVITE is a 2-part clinical trial designed to evaluate the safety, feasibility, and patient experience of administering intravesical bladder cancer therapies in the home.

One notable trend is the shift of therapies originally reserved for heavily pretreated, castration-resistant prostate cancer into earlier phases of disease.

The ENLIGHTED trial is evaluating the safety and efficacy of padeliporfin vascular targeted photodynamic therapy for low-grade upper tract urothelial carcinoma.

The 510(k) clearance was supported by 12-month data from the VAPOR 2 trial, which were presented at the 2025 SUO Annual Meeting.

Sameena A. Rahman, MD, emphasizes that menopause care requires precision medicine rather than a one-size-fits-all approach.

Leila Momtazi-Mar notes that although some studies suggest a decline in retrieval rates after age 40, this association remains preliminary.

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses key findings from the phase 3 POTOMAC trial and other studies of BCG/ICI combinations in high-risk NMIBC.

Mills describes TRT not merely as a prescription but as an ongoing therapeutic relationship aimed at comprehensive, long-term wellness.

Beyond rectal protection, rectal spacers may facilitate curative radiation dosing and reduce the likelihood of local recurrence.

Schmidt notes that differences in response rates between disease subtypes largely reflect inherent tumor biology.

Once patients are ready to explore treatment, Fosnight stresses the importance of shared decision-making.

The data, presented at ESMO, support a role for gemcitabine intravesical system plus cetrelimab in MIBC.

Nicholas Deebel, MD, shared key takeaways from a recent review outlining the current evidence on post-vasectomy pain syndrome.

A key finding was that 86% of patients required no additional therapy after receiving nadofaragene.

Muhammed A. Moukhtar Hammad, MBBCh, highlights ongoing work to develop a machine learning model to predict inflatable penile prothesis complications.